BOK Financial’s Alaunos Therapeutics TCRT Stock Holding History
Bought
Maintained
Sold
Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
---|---|---|---|---|---|---|---|---|
2025
Q2 | $320 | Hold |
66
| – | – | ﹤0.01% | 1128 |
|
2025
Q1 | $97 | Hold |
66
| – | – | ﹤0.01% | 1275 |
|
2024
Q4 | $112 | Hold |
66
| – | – | ﹤0.01% | 1284 |
|
2024
Q3 | $181 | Buy |
+66
| New | +$181 | ﹤0.01% | 1343 |
|
2024
Q1 | – | Sell |
-67
| Closed | -$707 | – | 1328 |
|
2023
Q4 | $707 | Hold |
67
| – | – | ﹤0.01% | 1170 |
|
2023
Q3 | $800 | Hold |
67
| – | – | ﹤0.01% | 1094 |
|
2023
Q2 | $5.1K | Hold |
67
| – | – | ﹤0.01% | 971 |
|
2023
Q1 | $6.3K | Hold |
67
| – | – | ﹤0.01% | 1027 |
|
2022
Q4 | $6.49K | Hold |
67
| – | – | ﹤0.01% | 890 |
|
2022
Q3 | $17K | Hold |
67
| – | – | ﹤0.01% | 887 |
|
2022
Q2 | $12K | Hold |
67
| – | – | ﹤0.01% | 905 |
|
2022
Q1 | $7K | Hold |
67
| – | – | ﹤0.01% | 972 |
|
2021
Q4 | $11K | Sell |
67
-18
| -21% | -$2.96K | ﹤0.01% | 975 |
|
2021
Q3 | $23K | Buy |
+85
| New | +$23K | ﹤0.01% | 947 |
|
2021
Q1 | $36K | Hold |
67
| – | – | ﹤0.01% | 902 |
|
2020
Q4 | $25K | Hold |
67
| – | – | ﹤0.01% | 901 |
|
2020
Q3 | $25K | Hold |
67
| – | – | ﹤0.01% | 850 |
|
2020
Q2 | $33K | Hold |
67
| – | – | ﹤0.01% | 845 |
|
2020
Q1 | $25K | Hold |
67
| – | – | ﹤0.01% | 820 |
|
2019
Q4 | $47K | Hold |
67
| – | – | ﹤0.01% | 922 |
|
2019
Q3 | $43K | Hold |
67
| – | – | ﹤0.01% | 896 |
|
2019
Q2 | $58K | Hold |
67
| – | – | ﹤0.01% | 893 |
|
2019
Q1 | $39K | Hold |
67
| – | – | ﹤0.01% | 897 |
|
2018
Q4 | $19K | Hold |
67
| – | – | ﹤0.01% | 872 |
|
2018
Q3 | $32K | Hold |
67
| – | – | ﹤0.01% | 915 |
|
2018
Q2 | $30K | Hold |
67
| – | – | ﹤0.01% | 909 |
|
2018
Q1 | $39K | Hold |
67
| – | – | ﹤0.01% | 900 |
|
2017
Q4 | $41K | Hold |
67
| – | – | ﹤0.01% | 910 |
|
2017
Q3 | $61K | Hold |
67
| – | – | ﹤0.01% | 967 |
|
2017
Q2 | $62K | Hold |
67
| – | – | ﹤0.01% | 868 |
|
2017
Q1 | $63K | Hold |
67
| – | – | ﹤0.01% | 863 |
|
2016
Q4 | $54K | Hold |
67
| – | – | ﹤0.01% | 866 |
|
2016
Q3 | $57K | Buy |
+67
| New | +$57K | ﹤0.01% | 864 |
|